Sept. 3, 2019 Price forecast | 2 weeks: 1.55% | 1 month: 1.60% | 3 months: 1.35%


LGND stock forecast

Our latest prediction for Ligand Pharmaceuticals, Inc.'s stock price was made on the Sept. 3, 2019 when the stock price was at 87.17$.

In the short term (2weeks), LGND's stock price should outperform the market by 1.55%. During that period the price should oscillate between -4.77% and +6.59%.

In the medium term (3months), LGND's stock price should outperform the market by 1.35%. During that period the price should oscillate between -12.58% and +16.57%.


About Ligand Pharmaceuticals, Inc.

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

At the moment the company generates 174M USD in revenues.

On its last earning announcement, the company reported a profit of 32.49$ per share.

The book value per share is 29.37$

Ligand Pharmaceuticals, Inc. website


Three months stock forecastSept. 3, 2019


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
174M 93.90% 66M 38.10% 677M 32.49 - - 22M 29.37 44M - 32M